XORTX Therapeutics Inc. (TSXV:XRTX)
3.190
0.00 (0.00%)
Inactive · Last trade price on Aug 31, 2026
XORTX Therapeutics Employees
As of December 31, 2023, XORTX Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
5.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2023 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2022 | 3 | 0 | - | 3 | 0 |
| Jan 1, 2022 | 3 | - | - | 3 | 0 |
XORTX Therapeutics News
- 10 days ago - XORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock Up - Nasdaq
- 10 days ago - XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout - Financial Post
- 10 days ago - XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout - GlobeNewsWire
- 4 weeks ago - XRTX Therapeutics (XRTX) Advances Gout Treatment Program with IND Submission Plans - GuruFocus
- 4 weeks ago - XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year - Nasdaq
- 4 weeks ago - Xortx Therapeutics announces planned FDA IND submission for XRx-026 - TheFly
- 4 weeks ago - XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity - Financial Post
- 4 weeks ago - XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity - GlobeNewsWire